Company intelligence / Profile preview
Mitotherapeutix
Farmington, Connecticut, United Statesmitotherapeutix.com ↗
- Ownership
- Private
- Employees
- ~7
- Development stage
- Preclinical
01
Overview
Mitotherapeutix is developing MT-101, an siRNA drug designed to transiently eliminate MCJ, a negative regulator of mitochondrial metabolism. The drug has shown promising results in mice, rats, and non-human primates, demonstrating favorable impacts on lipid levels, triglycerides, liver enzymes, and fibrosis. The company expects to file an IND in the fourth quarter of 2024.
- Therapeutic areas
- GastroenterologyMetabolic DisordersOncology
- Modalities
- siRNA (small interfering RNA)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on Mitotherapeutix.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mitotherapeutix.